NOXXON Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment. All its product candidates are based on a new class of drug called Spiegelmers, which are identified and synthesized through a proprietary discovery platform which the Group believes offers specific advantages over other drug classes. All operational activities are conducted in Berlin.NOXXON Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment.